Brady James Parker
Known title: Chief Human Resources OfficerCIK: 0002088887
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 1,976 | $8K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 13,160 | $51K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,846 | $12K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,234 | $13K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 309 | $2K | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 99,455 | $0 | 1/23/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.